Jardiance Side Effects: Delayed-Onset Adverse Events You Should Know

Why Delayed-Onset Side Effects Are Easily Missed With Jardiance

Most prescribers counsel patients on the immediate effects of empagliflozin: genital mycotic infections, polyuria, and mild volume depletion that typically appear in the first two weeks. Those early events are expected and usually self-limited.

The more dangerous problem is the category of side effects that appear weeks to many months after a patient starts the drug, when both the patient and clinician may have concluded that therapy is well tolerated. By that point, the mental link between Jardiance and a new symptom can be broken.

This article focuses specifically on those time-delayed signals, drawing on the EMPA-REG OUTCOME trial, FDA FAERS data, the 2023 empagliflozin prescribing label, and post-marketing case literature.

How SGLT2 Inhibition Creates a Delayed Risk Profile

Empagliflozin blocks the sodium-glucose cotransporter-2 in the proximal tubule, increasing urinary glucose excretion by roughly 70 to 90 grams per day. That glucosuria creates a persistently altered urinary environment and a mild caloric deficit that shifts substrate metabolism toward free fatty acid oxidation. Neither of those changes is acutely dangerous, but over weeks they accumulate into measurable risks: a urinary tract colonized by glucose-hungry organisms, and a metabolic state primed for ketogenesis if a physiological stressor occurs.

The Endocrine Society's 2022 clinical practice guideline on diabetes pharmacotherapy notes that SGLT2-inhibitor risks "tend to emerge during extended use rather than during initial titration," a pattern that distinguishes this drug class from most other oral antidiabetics. [1]

Euglycemic Diabetic Ketoacidosis (euDKA)

Euglycemic DKA is the delayed adverse event that carries the highest mortality risk. It can appear anywhere from 72 hours to several months after starting empagliflozin, and the normal blood glucose level consistently fools both patients and emergency physicians.

Why the Glucose Is Normal

Empagliflozin increases renal glucose excretion even as ketone bodies accumulate. The result is severe metabolic acidosis with a blood glucose that may be as low as 140 to 200 mg/dL. A standard fingerstick glucose check will appear reassuring. The diagnosis requires a venous blood gas, serum bicarbonate, and serum or urine ketones.

A 2020 review in Diabetes Care analyzed 71 euDKA cases associated with SGLT2 inhibitors and found that 73% of patients initially received an incorrect diagnosis, most commonly gastroenteritis or viral illness. [2] Median time from hospital presentation to correct diagnosis was 17 hours.

Precipitating Factors

The euDKA risk is not uniformly distributed across empagliflozin users. The FDA's 2020 drug safety communication identified several specific triggers that markedly increase risk [3]:

• Prolonged fasting or low-carbohydrate diets (ketogenic diets in particular)
• Major surgery, with particular concern for same-day procedures where the drug is not held
• Heavy alcohol consumption
• Insulin dose reduction or omission in patients with type 1 diabetes (empagliflozin is not FDA-approved for type 1 diabetes but is used off-label)
• Acute illness with reduced oral intake

The 2023 prescribing label for Jardiance now carries explicit guidance to hold the drug at least 3 days before planned surgery. [4]

Numbers From Post-Marketing Surveillance

A 2019 BMJ analysis of the FDA Adverse Event Reporting System (FAERS) found that SGLT2 inhibitors as a class carried a reporting odds ratio (ROR) of 9.7 (95% CI 8.4 to 11.2) for DKA compared with other antidiabetic agents. Empagliflozin-specific FAERS data through 2022 include over 400 individual DKA case reports. [5]

Fournier's Gangrene (Necrotizing Fasciitis of the Perineum)

Fournier's gangrene is a rapidly progressive, polymicrobial necrotizing infection of the perineal and genital soft tissues. It is rare in the general population: approximately 1.6 cases per 100,000 person-years. In 2018, the FDA identified a disproportionate signal in SGLT2 inhibitor users and issued a Drug Safety Communication requiring label updates for the entire class. [6]

Timeline and Presentation

Onset in published SGLT2-associated cases has ranged from 5 to 49 days after drug initiation, with a median near 12 days based on the FDA's initial case series of 12 patients reported between 2013 and 2018. All 12 required surgical debridement; one patient died.

The presenting symptoms are easy to attribute to a common genital yeast infection in the early hours: perineal pain, swelling, and erythema. The distinguishing features are rapid progression, extension beyond the genitalia, crepitus on palpation, and systemic signs of sepsis. Any patient on empagliflozin who presents with perineal pain plus fever should have this diagnosis excluded before discharge.

Biological Mechanism

The sustained glucosuria produced by empagliflozin creates a tissue glucose gradient that favors bacterial growth by organisms including Bacteroides fragilis, Clostridium species, and Enterococcus. The concurrent mild immunosuppression from hyperglycemia in poorly controlled diabetes may amplify this risk, though Fournier's cases have been reported in patients with well-controlled HbA1c. [6]

Clinical decision framework: When to suspect Fournier's gangrene in an empagliflozin user

| Feature | Low Suspicion | High Suspicion | |---|---|---| | Duration on Jardiance | Over 6 months | 5 to 60 days | | Perineal symptoms | Itch only | Pain + swelling | | Systemic signs | Absent | Fever, tachycardia | | Skin exam | Erythema only | Induration, crepitus | | Labs | Normal WBC | WBC >15,000, elevated lactate |

Serious Urinary Tract Infections and Urosepsis

Uncomplicated UTIs are an early and well-recognized effect of SGLT2 inhibitors. The delayed concern is progression to pyelonephritis or urosepsis, which typically becomes apparent 4 to 12 weeks into therapy, often after the prescriber and patient have normalized the idea that mild urinary symptoms are part of the drug's profile.

Trial Data on Serious UTI Events

In EMPA-REG OUTCOME (N=7,020, median follow-up 3.1 years), serious UTIs including urosepsis occurred in 0.4% of empagliflozin-treated patients versus 0.3% in the placebo group. While the absolute difference is small, the trial was not powered to detect rare infectious adverse events, and post-marketing surveillance consistently shows a higher signal. [7]

A 2021 pharmacovigilance study published in JAMA Internal Medicine reviewed FAERS data for all SGLT2 inhibitors and found a statistically significant signal for urosepsis, with an ROR of 3.7 (95% CI 2.8 to 4.9) compared with dipeptidyl peptidase-4 (DPP-4) inhibitors. [8]

Who Is at Highest Risk

Women with a history of recurrent UTIs, patients with urologic abnormalities, and older adults with incomplete bladder emptying carry the greatest risk for serious urinary infection on empagliflozin. The 2023 Jardiance label advises clinicians to evaluate patients for signs of UTI before and periodically during treatment in these populations. [4]

Lower-Limb Amputation Signal

The CANVAS trial of canagliflozin (a related SGLT2 inhibitor) reported a near-doubling of lower-limb amputation risk. This finding generated substantial regulatory scrutiny of the entire SGLT2 class, including empagliflozin.

What EMPA-REG OUTCOME Showed

EMPA-REG OUTCOME did not find a statistically significant increase in amputation rates. The empagliflozin group had an amputation rate of 1.0% compared with 1.1% in placebo (hazard ratio 0.90, 95% CI 0.63 to 1.30). [7] The FDA nonetheless extended its amputation safety review to empagliflozin in 2017 and concluded the evidence was insufficient to mandate a label change specific to empagliflozin.

The clinical implication is that patients with established peripheral arterial disease (PAD) or prior amputation remain a population requiring careful monitoring during extended empagliflozin use. The delayed nature of vascular ischemia means that any new foot ulcer or change in lower-limb perfusion in a patient on Jardiance warrants prompt vascular surgery referral rather than watchful waiting.

Practical Foot-Care Guidance

The American Diabetes Association Standards of Care 2024 recommend comprehensive foot exams at every visit for patients with PAD who are using SGLT2 inhibitors. [9] Patients should be instructed to inspect both feet daily and report any new ulceration, discoloration, or unusual warmth within 48 hours.

Bone Density and Fracture Risk

Empagliflozin's effect on bone is more subtle than the other delayed risks above, but the timeline extends to 1 to 2 years before measurable changes in bone mineral density (BMD) are detectable by DXA scanning.

Mechanism of Bone Effect

SGLT2 inhibition increases renal phosphate reabsorption and raises serum phosphate, which in turn suppresses parathyroid hormone. The resulting alterations in the calcium-phosphate-PTH axis may reduce bone formation over time. Urinary calcium losses from volume depletion add a secondary mechanism.

A 2022 meta-analysis published in JBMR (Journal of Bone and Mineral Research) pooling data from 14 randomized controlled trials of SGLT2 inhibitors (N=12,847) found a small but statistically significant reduction in BMD at the total hip (mean difference -0.45%, 95% CI -0.71% to -0.19%, P<0.01) at 2 years. [10] No significant change was seen at the lumbar spine.

Fracture Incidence in Trials

EMPA-REG OUTCOME reported fractures in 2.7% of empagliflozin patients versus 3.0% in placebo (not statistically significant). [7] The fracture signal in SGLT2 data as a class is inconsistent across trials, and current evidence does not support routine DXA monitoring for all empagliflozin users. Clinicians should consider baseline and periodic BMD assessment in patients already at elevated fracture risk: postmenopausal women, adults over 70, and those on concurrent corticosteroids.

Volume Depletion and Acute Kidney Injury: A Delayed Complication Pattern

Acute kidney injury (AKI) from empagliflozin is not truly delayed in mechanism, but in practice it appears weeks to months after initiation for a specific reason: patients often do not reduce their baseline diuretic or antihypertensive doses when starting the drug, and the combined volume depletion effect accumulates gradually.

FAERS and Trial Data

An FDA Drug Safety Communication issued in June 2016 specifically addressed AKI risk with SGLT2 inhibitors, including empagliflozin. The agency identified 101 cases of AKI requiring hospitalization or dialysis in FAERS, with a median time to onset of 43 days after drug initiation. [11] This 6-week median onset is characteristic of the delayed pattern: the drug has been tolerated, baseline creatinine has not been rechecked, and an intercurrent illness or dietary change tips the patient into acute tubular injury.

EMPA-REG OUTCOME notably showed a renoprotective signal (37% relative risk reduction in doubling of serum creatinine) at the population level. [7] That benefit does not preclude AKI in vulnerable individuals, specifically those with eGFR <45 mL/min/1.73m2, active diuretic use, or dehydration.

The eGFR Threshold

The 2023 Jardiance prescribing label states that empagliflozin is not recommended when eGFR is persistently below 20 mL/min/1.73m2 for heart failure indications and should not be initiated for glycemic control when eGFR is below 30. Rechecking serum creatinine and electrolytes at 4 to 6 weeks after initiation and after any febrile illness or volume-depleting event catches the largest proportion of delayed AKI cases early. [4]

Drug Interactions That Extend the Risk Window

Some delayed adverse events are amplified by medications commonly added months into a patient's treatment course.

Loop diuretics added for edema management increase volume depletion risk synergistically. A 2021 JAMA Internal Medicine cohort study found that patients starting furosemide while already on an SGLT2 inhibitor had a 2.3-fold higher AKI rate than those on furosemide alone. [8]

NSAIDs taken for musculoskeletal complaints (common in the diabetes population) further reduce renal perfusion on top of empagliflozin-induced volume contraction. Patients should be counseled to choose acetaminophen over ibuprofen or naproxen for routine pain management and to notify their prescriber before starting any NSAID course longer than 3 days.

Insulin dose changes in patients using empagliflozin off-label for type 1 diabetes or adjunctively in type 2 diabetes alter the euDKA risk substantially. Each 20% or greater reduction in total daily insulin dose should prompt temporary carbohydrate intake monitoring and ketone testing for at least 72 hours.

Monitoring Schedule Recommended for Delayed-Onset Risk Mitigation

Based on the adverse-event timelines documented in FAERS, EMPA-REG OUTCOME, and the 2023 prescribing label, a practical monitoring schedule for patients starting empagliflozin looks like this:

Weeks 1 to 2: Assess volume status (orthostatic BP, weight change), genital hygiene symptoms.

Weeks 4 to 6: Repeat serum creatinine, eGFR, and electrolytes. Ask specifically about perineal pain or unusual genital symptoms.

Months 2 to 3: Review urinary symptoms in detail. If recurrent UTI history exists, obtain urine culture even in the absence of symptoms.

Month 6 and annually: Comprehensive foot exam in patients with PAD or neuropathy. HbA1c, renal panel. Review concurrent medications added since initiation.

Before any planned surgery: Confirm empagliflozin is held for a minimum of 3 days (or longer for major procedures per institutional protocol). Obtain blood ketones or urine ketones on the morning of surgery regardless of blood glucose. [4]

FDA Label Language and Regulatory History

The Jardiance prescribing information has been updated multiple times since the drug's 2014 approval, specifically to add delayed-risk language. Key label revisions include:

• 2016: AKI warning added following FAERS review. [11]
• 2018: Fournier's gangrene warning added to Warnings and Precautions and to the Medication Guide for patients. [6]
• 2020: Perioperative DKA risk language strengthened; 3-day pre-surgical hold formalized. [3]
• 2023: Current label reiterates all the above and adds specific guidance on monitoring for patients with CKD stages 3b to 4. [4]

The FDA's MedWatch program continues to accept reports at fda.gov/safety/medwatch. Clinicians who observe a suspected delayed adverse event should file a report, because FAERS-generated signals are the primary regulatory mechanism for identifying new post-marketing safety concerns.

Patient Counseling Points for Delayed Side Effects

Patients leave the pharmacy with a Medication Guide, but that document is dense and does not emphasize timing. A brief verbal summary of the three delayed risks most likely to be missed can improve early recognition:

1. "If you feel extremely sick with nausea, vomiting, or belly pain and your blood sugar reads normal or only slightly elevated, go to the emergency room and tell them you take Jardiance. This can be a serious acid problem even with a normal sugar."

2. "Pain, swelling, or redness in your genital area that spreads or is getting worse after 24 to 48 hours of treatment is a medical emergency. Do not wait for it to resolve on its own."

3. "If you become dehydrated from vomiting, diarrhea, or intense heat and exercise, hold Jardiance that day and rehydrate. Restart only after you have been able to eat and drink normally for 24 hours."

These three instructions address euDKA, Fournier's gangrene, and volume-depletion-associated AKI respectively, the three delayed events with the highest mortality and morbidity in post-marketing literature.